Zymeworks - Model ZW49 - Bispecific Antibody Drug Conjugate (ADC)
From Pipeline
ZW49 is a HER2-targeted antibody drug conjugate (ADC) developed using Zymeworks’ proprietary Azymetric™ and ZymeLink™ platforms. ZW49 is currently being evaluated in a Phase 1 clinical trial as a treatment for patients with locally advanced or metastatic HER2-expressing cancers that have progressed following treatment with existing approved therapies, including HER2-targeted agents. ZW49 combines the unique design of zanidatamab with a proprietary cytotoxin and cleavable linker. ZW49 delivers a novel auristatin (cell-killing compound) to tumor cells by taking advantage of the enhanced antibody-HER2 internalization of zanidatamab.
-
Most popular related searches
Indications
- HER2-Expressing Cancers
Customer reviews
No reviews were found for Zymeworks - Model ZW49 - Bispecific Antibody Drug Conjugate (ADC). Be the first to review!